Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February28, 2019, Esperion Therapeutics,Inc. issued a press release announcing its financial results for the three months and year-ended December31, 2018 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit99.1.
The information set forth under Item 2.02 and in Exhibit99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Item 2.02 Other Events
On February28, 2019, Esperion Therapeutics,Inc. issued a press release titled, “Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet”. A copy of the press release is filed herewith as Exhibit99.2 and is incorporated herein by reference.
Item 2.02 Financial Statements and Exhibits.
(d)Exhibits
Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a19-5056_1ex99d1.htm EX-99.1 Exhibit 99.1 Investor Contact: Alex Schwartz Esperion 734-249-3386 [email protected] Media Contact: Elliot Fox W2O Group 212-257-6724 [email protected] Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results ANN ARBOR,…
To view the full exhibit click here
About Esperion Therapeutics,Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.
